Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Part of paid clinical trials in Irvine, California.

Sponsor
ACADIA Pharmaceuticals Inc.
Study ID
NCT07095465
Phase
PHASE3
Status
Enrolling By Invitation

Conditions

  • Lewy Body Dementia Psychosis

Eligibility Criteria

Sex
ALL
Age
55 Years - 84 Years
Healthy Volunteers
Not accepted

Interventions

  • ACP-204 — DRUG
    Provided as 1 capsule, to be taken orally once daily

Study Details

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Key Dates

Start date
Nov 14, 2025
Status verified
Jul 2025
Primary completion
Feb 28, 2029
Completion
Mar 31, 2029

Study Design

Enrollment
126 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ACP-204
    Initiation of treatment with ACP-204 at a dose of 30 mg once daily. During the trial, the dose may be adjusted, i.e. uptitration to 60 mg in case of suboptimal efficacy or subsequent down titration to 30 mg. Repeated titration steps are allowed.

Primary Outcome Measure

Proportion of subjects who experience treatment-emergent adverse events (TEAEs) [ Time Frame: 52 weeks ]

Locations (13)

Find similar trials in Irvine, CA

Related Studies